- Home
- NTB vs GLPG Comparison
NTB vs GLPG Comparison
Compare NTB & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NTB | GLPG |
|---|---|---|
| Founded | 1858 | 1999 |
| Country | Bermuda | Belgium |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2016 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NTB | GLPG |
|---|---|---|
| Price | $51.96 | $31.52 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $50.67 | $31.33 |
| AVG Volume (30 Days) | ★ 159.4K | 84.8K |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | ★ 17.07 | N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $599,452,000.00 | $336,643,201.00 |
| Revenue This Year | $4.46 | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | 4.60 | ★ 10.31 |
| 52 Week Low | $34.77 | $22.36 |
| 52 Week High | $51.83 | $37.78 |
Technical Indicators
Market Signals| Indicator | NTB | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 82.82 | 50.49 |
| Support Level | $50.80 | $30.73 |
| Resistance Level | $51.83 | $32.75 |
| Average True Range (ATR) | 0.91 | 0.58 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 95.06 | 44.44 |
Price Performance
Historical ComparisonAbout NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.